ML20125C300
| ML20125C300 | |
| Person / Time | |
|---|---|
| Issue date: | 07/30/1979 |
| From: | Ahearne J NRC COMMISSION (OCM) |
| To: | Harold Denton Office of Nuclear Reactor Regulation |
| Shared Package | |
| ML20125C287 | List: |
| References | |
| NUDOCS 8001080329 | |
| Download: ML20125C300 (1) | |
Text
,'
e-
,e
- y.n nc,.
u
'cq UN!TED STATES i
' 8 /2.r:,, in"I ^n NUCLEAR REGULATORY COM."MSSION (G q[$((M.',.. y e
WA3HlN GT ON. D.C. 20555
%lf.~%'#,E M,
July 30, 1979 0
OFFtO OF THE COh.MISSIONER r a I:E."J P>.i;0 0,': FORi Harold Denton, ire.ctor, f!RR f.,
FROM:
John Ahearne g) 7 c..%.___.
USEOFTHYROID(DLOCKINGAGEfiTS
SUBJECT:
Thank you for your remorandum of July 13 on this subject.
As you pointed cut "The f;RC staff has been predisposed to require stockpiling of KI."
You also noted that the Reg Guide 1.101 recommendation was e,ualified because the Food and Drug Administration had not developed guidance for the use of radioprotective drugs.
I understar.d the FDA has published a Federal Register tiotice on the use of KI indicating that it is effective and the FDA does not have any problem w!:h its use.
Your July 13 neurar.dum indicates that "The f;RC staff will be teeting wich FDA in the near future to expedite consideration of the c.a tter. "
I would appreciate knowing what it is that must be expedited and wher the meeting wi th FDA will be held.
Also, I conclude from your renorandur that it had only been FDA in action that had prevented the IT fro recuirin? stockpilino of KI.filow that the FDA has acted, do we inter.d to npase such a requirement?
cc:
Ch:.irran Hendrie Com'issioner Gilir. sky Commissicner Kennedy Co.aissioner Bradford 90009276 ED0 /, i Secy
/ 'T Rec'd OH. EDO Date.
.7.'!.l.Y..-c?
i.mc.
....,r.. O.... w 8001080.327